Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombospondin 1 | 2 | 2009 | 55 | 0.650 |
Why?
|
| Sentinel Lymph Node | 2 | 2017 | 216 | 0.630 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 1415 | 0.450 |
Why?
|
| Neoadjuvant Therapy | 4 | 2017 | 4975 | 0.450 |
Why?
|
| Peptide Fragments | 2 | 2009 | 1271 | 0.440 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2017 | 509 | 0.430 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 1026 | 0.400 |
Why?
|
| Carrier Proteins | 2 | 2009 | 2022 | 0.370 |
Why?
|
| Peripheral Nerves | 1 | 2009 | 159 | 0.340 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 72 | 0.340 |
Why?
|
| Breast Neoplasms | 6 | 2024 | 15694 | 0.320 |
Why?
|
| Colectomy | 1 | 2009 | 288 | 0.290 |
Why?
|
| Hospitals, Veterans | 1 | 2009 | 397 | 0.290 |
Why?
|
| Colorectal Neoplasms | 4 | 2011 | 3578 | 0.280 |
Why?
|
| Mastectomy | 3 | 2024 | 1534 | 0.280 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2009 | 605 | 0.260 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 585 | 0.240 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 4844 | 0.220 |
Why?
|
| Adenocarcinoma | 3 | 2011 | 7789 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 860 | 0.200 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 1202 | 0.190 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 129 | 0.170 |
Why?
|
| Sarcoma | 1 | 2009 | 1725 | 0.170 |
Why?
|
| Veterans | 1 | 2009 | 1641 | 0.150 |
Why?
|
| Patient Participation | 1 | 2021 | 446 | 0.150 |
Why?
|
| Disease-Free Survival | 4 | 2014 | 10001 | 0.140 |
Why?
|
| Mammaplasty | 1 | 2024 | 780 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 622 | 0.130 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2009 | 589 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 10035 | 0.130 |
Why?
|
| Aged | 10 | 2021 | 70117 | 0.120 |
Why?
|
| Middle Aged | 11 | 2024 | 86204 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2014 | 185 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2014 | 234 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2021 | 12873 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 1209 | 0.110 |
Why?
|
| RNA-Binding Proteins | 2 | 2009 | 984 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1742 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2011 | 3890 | 0.110 |
Why?
|
| Adult | 9 | 2021 | 77950 | 0.100 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 13658 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2009 | 3981 | 0.100 |
Why?
|
| Female | 12 | 2024 | 141928 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 29902 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 8865 | 0.090 |
Why?
|
| Gelatinases | 1 | 2009 | 52 | 0.090 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2009 | 43 | 0.090 |
Why?
|
| CD36 Antigens | 1 | 2009 | 53 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 1959 | 0.090 |
Why?
|
| Humans | 14 | 2024 | 261506 | 0.080 |
Why?
|
| Neurogenesis | 1 | 2011 | 238 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 4892 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 14289 | 0.080 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2014 | 716 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 2518 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2017 | 6100 | 0.080 |
Why?
|
| Prognosis | 4 | 2021 | 21713 | 0.070 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 275 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 280 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1960 | 0.070 |
Why?
|
| Risk | 1 | 2011 | 1972 | 0.070 |
Why?
|
| Young Adult | 2 | 2017 | 21445 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2011 | 1656 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2009 | 7222 | 0.070 |
Why?
|
| Spleen | 1 | 2007 | 676 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2009 | 518 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 7702 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 2231 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2292 | 0.060 |
Why?
|
| Colon | 1 | 2007 | 670 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2009 | 2450 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 2314 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2009 | 5395 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2009 | 1824 | 0.050 |
Why?
|
| Quality of Life | 2 | 2021 | 4532 | 0.050 |
Why?
|
| Survival Rate | 1 | 2014 | 12221 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2007 | 4307 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6207 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2014 | 37905 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2007 | 3821 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 750 | 0.040 |
Why?
|
| Technetium | 1 | 2017 | 77 | 0.040 |
Why?
|
| Mastectomy, Simple | 1 | 2017 | 58 | 0.040 |
Why?
|
| Breast | 1 | 2024 | 1344 | 0.040 |
Why?
|
| Rosaniline Dyes | 1 | 2017 | 108 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2017 | 275 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 611 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 764 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2007 | 2967 | 0.040 |
Why?
|
| Male | 4 | 2011 | 123000 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 14551 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 674 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 15862 | 0.030 |
Why?
|
| Axilla | 1 | 2017 | 902 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 256 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2021 | 1216 | 0.030 |
Why?
|
| Animals | 2 | 2009 | 59536 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 32848 | 0.030 |
Why?
|
| Trisomy | 1 | 2014 | 231 | 0.030 |
Why?
|
| Karyotyping | 1 | 2014 | 1022 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 5767 | 0.030 |
Why?
|
| United States | 1 | 2009 | 15433 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4314 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2009 | 11965 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2017 | 1863 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 760 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 5687 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2232 | 0.020 |
Why?
|
| Mice | 1 | 2007 | 34495 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 14889 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 6682 | 0.010 |
Why?
|